Skip to main content

Table 1 Characteristics of 249 chronic HBV-infected patients treated with pegylated interferon α-2a or nucleos(t)ide analogues

From: Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B

Characteristics ADV ETV LdT PEG-IFN-α-2a
(treatment naïve)
PEG-IFN-α-2a
(ETV experienced)
P value
Patients (n) 72 58 53 39 27  
Age (year) 28.69 ± 8.09 30.29 ± 8.55 28.62 ± 8.73 27.33 ± 6.47 30.11 ± 9.81 0.579a
Male sex [n (%)] 59(81.94%) 48(82.76%) 35(66.04%) 31(79.49%) 22(81.48%) 0.904b
HBV DNA (log10 copies/ml) 7.40 ± 0.94 7.58 ± 1.53 7.87 ± 1.32 8.17 ± 1.37 <2 0.019a
ALT (U/L) 172.5 ± 173.6 131.9 ± 128.6 176.1 ± 145.7 162.6 ± 92.12 31.32 ± 26.32 <0.0001c
AST (U/L) 95.44 ± 72.68 97.69 ± 152.4 122.7 ± 133.8 98.10 ± 55.33 29.25 ± 10.92 <0.0001c
BUN (mmol/L) 4.45 ± 0.98 4.37 ± 1.10 4.68 ± 1.27 4.87 ± 1.16 5.16 ± 1.34 0.025a
Cr (mg/dl) 0.93 ± 0.11 0.75 ± 0.12 0.74 ± 0.13 0.75 ± 0.11 0.77 ± 0.13 <0.0001a
CKD-EPI eGFR (mL/min/1.73 m2) 106.3 ± 13.99 121.2 ± 10.38 121.5 ± 11.21 123.1 ± 9.64 120.1 ± 11.50 <0.0001a
MDRD eGFR (mL/min/1.73 m2) 100.00 ± 14.68 127.7 ± 22.13 126.4 ± 20.96 127.4 ± 20.16 125.1 ± 22.69 <0.0001a
  1. Values are presented as mean ± SD or n (percentage). aOne-way ANOVA test. bChi-squared test. c Kruskal-Wallis test